| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Company Name: |
Musechem |
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
P-Selectin Inhibitor manufacturers
- PSI-697
-
- $962.00
-
2026-05-11
- CAS:851546-61-7
- Purity: 98.97%
- Supply Ability: 10g
|
| | P-Selectin Inhibitor Basic information |
| Product Name: | P-Selectin Inhibitor | | Synonyms: | P-Selectin Inhibitor;Benzo[h]quinoline-4-carboxylic acid, 2-[(4-chlorophenyl)methyl]-7,8,9,10-tetrahydro-3-hydroxy-;PSI 697,PSI697;PSI-697(P-Selectin Inhibitor);2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid;PSI-697 | | CAS: | 851546-61-7 | | MF: | C21H18ClNO3 | | MW: | 367.83 | | EINECS: | | | Product Categories: | | | Mol File: | 851546-61-7.mol |  |
| | P-Selectin Inhibitor Chemical Properties |
| Boiling point | 553.0±50.0 °C(Predicted) | | density | 1.383±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 45.8 mg/mL (124.51 mM) | | pka | 0.89±0.20(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | P-Selectin Inhibitor Usage And Synthesis |
| Uses | PSI-697 is an oral P-selectin inhibitor with an IC50 of 125 μM[1]. | | in vivo | PSI-697 (0-50 mg/kg; p.o.) significantly reduces the number of rolling leukocytes by 39% versus vehicle control[1].
PSI-697 (100 mg/kg; p.o.) reduces thrombus weight by 18% relative to vehicle, without prolonging bleeding time in a rat venous thrombosis model[1].
PSI-697 (30 mg/kg; p.o.; daily; 6 days) promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis[2].
PSI-697 ((30 mg/kg; i.g.; daily) decreases vein wall injury in a rat stenosis model of venous thrombosis[2].
| Animal Model: | 4-5 weeks male Sprague-Dawley rat (50-100 g)[1] | | Dosage: | 0 mg/kg, 30 mg/kg, 50 mg/kg | | Administration: | Oral administration | | Result: | At an oral dose of 50 mg/kg reduced the number of rolling leukocytes by 39% versus vehicle control. |
| | References | [1] Bedard PW et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther. DOI:10.1124/jpet.107.128124
[2] Myers DD Jr et al. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost. 2007 Mar;97(3):400-7. PMID:17334507
[3] Myers DD Jr et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006 Sep;44(3):625-32. DOI:10.1016/j.jvs.2006.05.021 |
| | P-Selectin Inhibitor Preparation Products And Raw materials |
|